A 71-year-old man with multimorbidity attends for review. He has type 2 diabetes, hypertension, chronic kidney disease stage 3a, ischaemic heart disease, and osteoarthritis. He reports difficulty managing his medication regimen and frequently forgets doses. His current pill burden is 9 tablets daily taken at different times. According to NICE guidance on multimorbidity, which approach is most appropriate to improve his medication adherence?
Q42
A 68-year-old man with asthma, type 2 diabetes, hypertension, gastro-oesophageal reflux disease, and chronic lower back pain attends for a medication review. His medications include beclometasone/formoterol inhaler, salbutamol as needed, metformin, sitagliptin, amlodipine, bendroflumethiazide, lansoprazole, and he has been taking ibuprofen 400mg three times daily for 8 months purchased over the counter for back pain. He reports his asthma has been more troublesome recently with increased salbutamol use. Blood pressure is 156/94 mmHg (usually well-controlled), and eGFR has declined from 68 to 56 ml/min/1.73m² over 6 months. When applying medication review principles to identify the medication-related problem, what is the most appropriate action?
Q43
A 70-year-old woman with type 2 diabetes, ischaemic heart disease, moderate-severe frailty (Clinical Frailty Scale 6), and dementia (MMSE 18/30) is reviewed following a fall resulting in a fractured wrist. She lives alone with twice-daily carer support. Her medications include aspirin, atorvastatin, ramipril, bisoprolol, metformin, gliclazide, alendronate, calcium/vitamin D, donepezil, and mirtazapine. Her daughter, who has lasting power of attorney for health and welfare, asks whether her mother should continue all these medications. Her HbA1c is 68 mmol/mol, and she has had no cardiovascular events for 6 years. When applying clinical reasoning to evaluate medication appropriateness in this scenario, which represents the most appropriate approach?
Q44
During a practice-based quality improvement project on medication reviews, you identify a 79-year-old man taking 14 regular medications for heart failure, atrial fibrillation, COPD, type 2 diabetes, gout, and osteoarthritis. He reports feeling overwhelmed by his medication regimen and admits missing doses frequently. His quality of life is poor with MRC dyspnoea scale 4, and he has been hospitalized twice in the past year with heart failure decompensation. When applying shared decision-making principles and evaluating treatment burden versus benefit in this context, which approach best represents contemporary evidence-based management of multimorbidity?
Q45
A 66-year-old woman attends for an annual medication review. She has rheumatoid arthritis (well-controlled for 5 years on methotrexate), type 2 diabetes, hypertension, and recurrent urinary tract infections. She takes methotrexate 15mg weekly, folic acid, hydroxychloroquine, omeprazole 20mg daily (started 5 years ago when methotrexate initiated), metformin, gliclazide, ramipril, and has recently been prescribed long-term nitrofurantoin 50mg at night as UTI prophylaxis by urology. Blood tests show eGFR 52 ml/min/1.73m², calcium 2.58 mmol/L, and vitamin B12 268 ng/L (normal >200). Applying structured medication review principles and analyzing medication appropriateness, which represents the priority concern?
Q46
You are analyzing prescribing data for patients with multimorbidity in your practice. A 72-year-old man with heart failure (LVEF 28%), type 2 diabetes, chronic kidney disease stage 3b, and ischaemic heart disease takes bisoprolol 10mg, ramipril 10mg, furosemide 80mg, spironolactone 25mg, dapagliflozin, metformin, aspirin, and atorvastatin. Recent bloods show Na+ 134 mmol/L, K+ 5.6 mmol/L, eGFR 32 ml/min/1.73m², HbA1c 65 mmol/mol, BP 116/68 mmHg. He is asymptomatic with no fluid overload. When analyzing the risks and benefits of his current regimen in the context of worsening renal function, which represents the most evidence-based approach to medication optimization?
Q47
A 74-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and orthostatic hypotension attends with his wife who reports he has been experiencing visual hallucinations and increased confusion over the past month. His medications include co-careldopa, ropinirole, selegiline, metformin, tamsulosin, and fludrocortisone. Examination reveals BP 142/86 mmHg sitting, 110/68 mmHg standing. MMSE is 22/30 (previously 26/30 six months ago). When analyzing the interaction between his conditions and medications causing cognitive decline, which medication modification represents the most appropriate initial strategy?
Q48
A 68-year-old woman with type 2 diabetes, hypertension, hypothyroidism, osteoporosis, and chronic pain syndrome attends for a medication review. She takes metformin, gliclazide, amlodipine, ramipril, levothyroxine, alendronate with calcium and vitamin D, and co-codamol 30/500 four times daily for 3 years. She reports ongoing lower back pain, constipation requiring regular laxatives, and daytime drowsiness affecting her daily activities. Her HbA1c is 62 mmol/mol. When applying structured medication review principles to optimize her management, which intervention should be prioritized?
Q49
During a comprehensive medication review for a 70-year-old man with COPD (post-bronchodilator FEV1 45% predicted), type 2 diabetes, ischaemic heart disease, and depression, you identify he is taking 11 regular medications including fluticasone/vilanterol inhaler, tiotropium, carbocisteine, bisoprolol, aspirin, atorvastatin, ramipril, metformin, sertraline, omeprazole, and paracetamol. He has had three chest infections requiring antibiotics in the past 12 months and reports persistent low mood despite sertraline 100mg daily. Applying the principles of medication optimization in multimorbidity, what is the most appropriate action?
Q50
A 75-year-old woman with heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, and chronic kidney disease stage 3a attends for review. She takes bisoprolol, furosemide, spironolactone, apixaban, digoxin, metformin, and atorvastatin. She reports experiencing nausea, visual disturbances with yellow-tinged vision, and palpitations over the past week. Her pulse is irregularly irregular at 48 bpm, BP 118/72 mmHg. ECG shows atrial fibrillation with slow ventricular response and frequent ventricular ectopics. Blood tests show Na+ 136 mmol/L, K+ 5.8 mmol/L, creatinine 142 μmol/L (baseline 125), and eGFR 36 ml/min/1.73m². Applying clinical reasoning to this polypharmacy scenario, what is the most appropriate immediate action?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 41: A 71-year-old man with multimorbidity attends for review. He has type 2 diabetes, hypertension, chronic kidney disease stage 3a, ischaemic heart disease, and osteoarthritis. He reports difficulty managing his medication regimen and frequently forgets doses. His current pill burden is 9 tablets daily taken at different times. According to NICE guidance on multimorbidity, which approach is most appropriate to improve his medication adherence?
A. Arrange for a family member to supervise all medication administration
B. Simplify the medication regimen by rationalising dosing schedules and exploring once-daily formulations (Correct Answer)
C. Provide written instructions with detailed timings for each medication
D. Prescribe all medications as liquid formulations to ease administration
E. Refer to secondary care for specialist management of each condition
Explanation: ***Simplify the medication regimen by rationalising dosing schedules and exploring once-daily formulations***- **NICE guideline NG56** specifically recommends reducing **treatment burden** by simplifying regimens to improve **medication adherence** in patients with multimorbidity.- Rationalising schedules and using **once-daily formulations** directly addresses the primary cause of this patient's non-adherence: the high **pill burden** and complex timing.*Arrange for a family member to supervise all medication administration*- While social support can be beneficial, this approach fails to address the **root cause** of the complex and burdensome medication regimen itself.- Undue reliance on family members can undermine the patient's **autonomy** and is not the first-line recommendation for improving adherence in cognitively capable patients.*Provide written instructions with detailed timings for each medication*- Written instructions may improve understanding, but they do not reduce the **cognitive load** or physical burden of taking nine different tablets at varying intervals.- Documentation alone does not simplify a **complex regimen**, which is the most significant barrier to adherence in this clinical scenario.*Prescribe all medications as liquid formulations to ease administration*- **Liquid formulations** are primarily indicated for patients with **dysphagia** (swallowing difficulties), which this patient does not report.- Switching to liquids does not reduce the number of doses per day and may even increase the complexity of **storing and measuring** multiple medications.*Refer to secondary care for specialist management of each condition*- Managing multimorbidity in multiple secondary care clinics often leads to **fragmented care** and potentially more complex, conflicting regimens.- **Primary care** is the most appropriate setting to provide an **integrated approach**, focusing on holistic care and the coordination of the patient's overall treatment plan.
Question 42: A 68-year-old man with asthma, type 2 diabetes, hypertension, gastro-oesophageal reflux disease, and chronic lower back pain attends for a medication review. His medications include beclometasone/formoterol inhaler, salbutamol as needed, metformin, sitagliptin, amlodipine, bendroflumethiazide, lansoprazole, and he has been taking ibuprofen 400mg three times daily for 8 months purchased over the counter for back pain. He reports his asthma has been more troublesome recently with increased salbutamol use. Blood pressure is 156/94 mmHg (usually well-controlled), and eGFR has declined from 68 to 56 ml/min/1.73m² over 6 months. When applying medication review principles to identify the medication-related problem, what is the most appropriate action?
A. Uptitrate beclometasone/formoterol dose as his asthma control has deteriorated
B. Add a third antihypertensive agent as blood pressure is above target despite dual therapy
C. Stop ibuprofen and explore non-pharmacological management for back pain, as it is likely causing multiple medication-related problems (Correct Answer)
D. Switch bendroflumethiazide to indapamide as it may be more effective for blood pressure control
E. Investigate for secondary causes of hypertension given previously good control
Explanation: ***Stop ibuprofen and explore non-pharmacological management for back pain, as it is likely causing multiple medication-related problems***
- **Ibuprofen** is a non-steroidal anti-inflammatory drug (**NSAID**) that is likely responsible for the patient's deteriorating **asthma control**, elevated **blood pressure**, and declining **renal function** (**eGFR**).
- **Multimorbidity** management requires identifying and removing medications that cause a **prescribing cascade**, where additional drugs are inappropriately added to treat side effects of an existing medication.
*Uptitrate beclometasone/formoterol dose as his asthma control has deteriorated*
- This action treats a symptom rather than the cause; up to 20% of adults with **asthma** have **NSAID-exacerbated respiratory disease**.
- Increasing the dose without removing the **ibuprofen** trigger would lead to unnecessary medication burden and potentially poor therapeutic response.
*Add a third antihypertensive agent as blood pressure is above target despite dual therapy*
- **NSAIDs** interfere with the efficacy of **antihypertensive medications** (like bendroflumethiazide) by promoting **sodium retention** and reducing renal prostaglandin synthesis.
- Adding more drugs instead of removing the **interfering agent** (**ibuprofen**) increases the risk of polypharmacy and side effects.
*Switch bendroflumethiazide to indapamide as it may be more effective for blood pressure control*
- While **indapamide** is a preferred thiazide-like diuretic, this change does not address the underlying **renal vasoconstriction** caused by chronic ibuprofen use.
- The priority in a **medication review** is to address clearly identifiable **drug-disease interactions** before switching therapeutic agents within the same class.
*Investigate for secondary causes of hypertension given previously good control*
- Extensive investigation for **secondary hypertension** is unnecessary at this stage, as a clear secondary cause (**chronic NSAID use**) has already been identified in the history.
- Clinical focus should remain on **deprescribing** the causative agent and monitoring for the reversal of clinical signs (**BP** and **eGFR**).
Question 43: A 70-year-old woman with type 2 diabetes, ischaemic heart disease, moderate-severe frailty (Clinical Frailty Scale 6), and dementia (MMSE 18/30) is reviewed following a fall resulting in a fractured wrist. She lives alone with twice-daily carer support. Her medications include aspirin, atorvastatin, ramipril, bisoprolol, metformin, gliclazide, alendronate, calcium/vitamin D, donepezil, and mirtazapine. Her daughter, who has lasting power of attorney for health and welfare, asks whether her mother should continue all these medications. Her HbA1c is 68 mmol/mol, and she has had no cardiovascular events for 6 years. When applying clinical reasoning to evaluate medication appropriateness in this scenario, which represents the most appropriate approach?
A. Continue all current medications as they are evidence-based and guideline-indicated for her conditions
B. Focus deprescribing on fall-risk medications: stop mirtazapine and reduce gliclazide dose initially
C. Engage in shared decision-making with daughter to establish goals of care, then align medication regimen with priorities, likely focusing on symptom control and quality of life over prognostic benefit (Correct Answer)
D. Stop statin and antiplatelet as life expectancy is limited and cardiovascular prevention is no longer relevant
E. Continue cardiovascular and diabetes medications but stop dementia medications as evidence of benefit is limited
Explanation: ***Engage in shared decision-making with daughter to establish goals of care, then align medication regimen with priorities, likely focusing on symptom control and quality of life over prognostic benefit***- For a patient with **moderate-severe frailty (CFS 6)**, **dementia**, and a recent fall, the focus of care shifts from aggressive disease management to **optimizing quality of life** and **minimizing harm** from polypharmacy.- **Shared decision-making** with the daughter, who holds **lasting power of attorney for health and welfare**, is crucial to align the medication regimen with the patient's values and established goals of care, such as **symptom control** and **fall prevention**.*Continue all current medications as they are evidence-based and guideline-indicated for her conditions*- This approach is inappropriate for a **frail, multimorbid elderly patient** as it risks **polypharmacy**, increased pill burden, and adverse drug reactions, including further falls.- Many guidelines are based on younger, healthier populations, and the **time-to-benefit** for some preventative medications may exceed this patient's **limited life expectancy**, offering little to no clinical advantage.*Focus deprescribing on fall-risk medications: stop mirtazapine and reduce gliclazide dose initially*- While deprescribing **fall-risk medications** like mirtazapine (sedation, anticholinergic effects) and gliclazide (hypoglycemia) is clinically relevant, this approach is **prescriptive** and bypasses the essential step of **shared decision-making**.- An initial focus solely on specific medications without establishing overall **goals of care** with the patient's legal representative is not the most appropriate comprehensive approach in this complex scenario.*Stop statin and antiplatelet as life expectancy is limited and cardiovascular prevention is no longer relevant*- While **deprescribing statins and antiplatelets** is often considered in patients with limited life expectancy or high frailty, unilaterally stopping them without a **discussion of goals of care** is not ideal.- Stopping these medications might align with a focus on **quality of life** over **prognostic benefit**, but this decision must be made in collaboration with the family through **shared decision-making**.*Continue cardiovascular and diabetes medications but stop dementia medications as evidence of benefit is limited*- This approach makes a **presumptive value judgment** about which conditions are most important, potentially overlooking the patient's and family's **priorities** regarding cognitive function and daily living.- While the evidence for **dementia medications** like donepezil can be modest, their discontinuation can sometimes lead to **worsening symptoms**; therefore, this should be part of a holistic review and shared decision-making, not a default action.
Question 44: During a practice-based quality improvement project on medication reviews, you identify a 79-year-old man taking 14 regular medications for heart failure, atrial fibrillation, COPD, type 2 diabetes, gout, and osteoarthritis. He reports feeling overwhelmed by his medication regimen and admits missing doses frequently. His quality of life is poor with MRC dyspnoea scale 4, and he has been hospitalized twice in the past year with heart failure decompensation. When applying shared decision-making principles and evaluating treatment burden versus benefit in this context, which approach best represents contemporary evidence-based management of multimorbidity?
A. Intensify monitoring and provide a dosette box to improve adherence to all guideline-indicated medications
B. Prioritize prognostic medications for life-limiting conditions while considering deprescribing symptom-only treatments, using patient priorities to guide decisions (Correct Answer)
C. Refer to specialist heart failure clinic for uptitration of therapy to prevent further hospitalization
D. Simplify regimen by stopping all non-essential medications and continue only cardiac medications
E. Continue current medications unchanged but provide detailed written instructions and education about each medication's importance
Explanation: ***Prioritize prognostic medications for life-limiting conditions while considering deprescribing symptom-only treatments, using patient priorities to guide decisions*** - This approach aligns with contemporary **evidence-based guidelines** for **multimorbidity**, such as those from **NICE**, advocating for **shared decision-making** to balance **treatment burden** against clinical benefit. - It focuses on medications providing **prognostic benefit** (e.g., for heart failure, COPD, diabetes) while systematically reviewing and potentially **deprescribing** those primarily for symptoms (e.g., osteoarthritis, gout if well-controlled) based on the patient's **quality of life** and priorities. *Intensify monitoring and provide a dosette box to improve adherence to all guideline-indicated medications* - While a dosette box can aid adherence, this approach fails to address the underlying problem of **polypharmacy** and the patient's stated feeling of being **overwhelmed** by the sheer number of medications. - Simply adhering to all **single-disease guidelines** in a patient with multimorbidity often leads to an excessive pill burden, increased risk of adverse drug reactions, and reduced overall quality of life. *Refer to specialist heart failure clinic for uptitration of therapy to prevent further hospitalization* - Referring for **uptitration** in this context would likely exacerbate the patient's already significant **pill burden** and sense of being overwhelmed, potentially worsening non-adherence. - A **specialist heart failure clinic** might focus primarily on optimizing cardiac outcomes, potentially overlooking the patient's holistic needs and the impact of other comorbidities or medications on their **quality of life**. *Simplify regimen by stopping all non-essential medications and continue only cardiac medications* - This approach is too aggressive and simplistic, potentially neglecting crucial treatments for conditions like **COPD** or **type 2 diabetes** that significantly impact the patient's health and functional status. - Arbitrarily stopping "non-essential" medications without a comprehensive, patient-centered review and **shared decision-making** process is not evidence-based and risks adverse outcomes. *Continue current medications unchanged but provide detailed written instructions and education about each medication's importance* - While education is important, it alone cannot mitigate the impact of an **excessive medication regimen** on a patient who explicitly states feeling **overwhelmed** and is missing doses. - This strategy fails to address the core issue of **treatment burden** and does not incorporate **patient priorities** or the potential for **deprescribing**, which are critical in multimorbidity management.
Question 45: A 66-year-old woman attends for an annual medication review. She has rheumatoid arthritis (well-controlled for 5 years on methotrexate), type 2 diabetes, hypertension, and recurrent urinary tract infections. She takes methotrexate 15mg weekly, folic acid, hydroxychloroquine, omeprazole 20mg daily (started 5 years ago when methotrexate initiated), metformin, gliclazide, ramipril, and has recently been prescribed long-term nitrofurantoin 50mg at night as UTI prophylaxis by urology. Blood tests show eGFR 52 ml/min/1.73m², calcium 2.58 mmol/L, and vitamin B12 268 ng/L (normal >200). Applying structured medication review principles and analyzing medication appropriateness, which represents the priority concern?
A. Omeprazole should be reviewed for discontinuation as long-term use without ongoing indication increases fracture and infection risk (Correct Answer)
B. Nitrofurantoin is contraindicated with eGFR <45 ml/min/1.73m² and should be changed to an alternative prophylactic agent
C. Gliclazide should be reviewed as it increases hypoglycaemia risk in the context of recurrent infections
D. Vitamin B12 level requires urgent replacement therapy as omeprazole-induced deficiency may be developing
E. Methotrexate dose should be reduced due to borderline renal impairment to prevent toxicity
Explanation: ***Omeprazole should be reviewed for discontinuation as long-term use without ongoing indication increases fracture and infection risk***- **Omeprazole** was likely initiated for gastroprotection when **methotrexate** was started; however, **PPIs** are not routinely indicated for methotrexate alone, especially if not combined with NSAIDs. After 5 years, the initial indication may no longer be relevant, and evidence for continued use should be assessed.- Long-term **Proton Pump Inhibitor (PPI)** use is associated with several adverse effects including increased risk of **osteoporotic fractures**, higher susceptibility to **Clostridioides difficile** infections, and malabsorption of **Vitamin B12** and magnesium, making its review a priority for patient safety.*Nitrofurantoin is contraindicated with eGFR <45 ml/min/1.73m² and should be changed to an alternative prophylactic agent*- Current **BNF guidelines** recommend avoiding **nitrofurantoin** if the **eGFR** is below 45 ml/min/1.73m² due to reduced renal excretion, leading to decreased efficacy in the urinary tract and increased risk of systemic toxicity, particularly **peripheral neuropathy**.- The patient's **eGFR is 52 ml/min/1.73m²**, which is above the contraindication threshold of 45 ml/min/1.73m², making its current use acceptable from a renal function perspective, though cautious monitoring is always advised in elderly patients.*Gliclazide should be reviewed as it increases hypoglycaemia risk in the context of recurrent infections*- **Sulfonylureas** like **gliclazide** do carry a risk of **hypoglycemia**, especially in elderly patients, those with renal impairment, or during acute illnesses like infection which can affect appetite or drug metabolism.- While it is a valid concern for long-term monitoring and patient education, the scenario does not present acute symptoms of hypoglycemia, nor does it represent an immediate, higher priority compared to addressing inappropriate **polypharmacy** with PPIs.*Vitamin B12 level requires urgent replacement therapy as omeprazole-induced deficiency may be developing*- The patient's **Vitamin B12** level is 268 ng/L, which falls within the stated **normal range** (>200 ng/L). Therefore, urgent replacement therapy is not indicated at this time.- Although long-term **omeprazole** and **metformin** use can both contribute to **Vitamin B12** malabsorption, the current level suggests a need for continued periodic monitoring rather than immediate intervention.*Methotrexate dose should be reduced due to borderline renal impairment to prevent toxicity*- For **methotrexate**, dose adjustments or cautious prescribing are typically required when the **eGFR** falls below 30 ml/min/1.73m² (indicating **Stage 4 Chronic Kidney Disease** or worse).- With an **eGFR of 52 ml/min/1.73m²** (Stage 3a CKD), the patient's renal function is generally considered sufficient to maintain the current weekly 15mg dose of **methotrexate** without an immediate need for reduction, especially given her rheumatoid arthritis is well-controlled.
Question 46: You are analyzing prescribing data for patients with multimorbidity in your practice. A 72-year-old man with heart failure (LVEF 28%), type 2 diabetes, chronic kidney disease stage 3b, and ischaemic heart disease takes bisoprolol 10mg, ramipril 10mg, furosemide 80mg, spironolactone 25mg, dapagliflozin, metformin, aspirin, and atorvastatin. Recent bloods show Na+ 134 mmol/L, K+ 5.6 mmol/L, eGFR 32 ml/min/1.73m², HbA1c 65 mmol/mol, BP 116/68 mmHg. He is asymptomatic with no fluid overload. When analyzing the risks and benefits of his current regimen in the context of worsening renal function, which represents the most evidence-based approach to medication optimization?
A. Stop spironolactone immediately due to hyperkalaemia and falling eGFR to prevent life-threatening complications
B. Continue current therapy unchanged as all medications are guideline-indicated and hyperkalaemia is mild
C. Reduce ramipril dose to 5mg to address hyperkalaemia while maintaining cardiovascular protection
D. Stop dapagliflozin as eGFR is approaching the threshold for discontinuation and it may contribute to hyperkalaemia
E. Continue spironolactone and add patiromer to manage hyperkalaemia while maintaining optimal prognostic therapy for heart failure (Correct Answer)
Explanation: ***Continue spironolactone and add patiromer to manage hyperkalaemia while maintaining optimal prognostic therapy for heart failure***- In patients with **heart failure with reduced ejection fraction (HFrEF)**, Mineralocorticoid Receptor Antagonists (MRAs) like **spironolactone** provide a significant mortality benefit that should be preserved if possible.- Evidence from the **DIAMOND trial** supports the use of potassium binders like **patiromer** to manage mild-to-moderate hyperkalaemia, allowing patients to remain on life-saving **RAAS inhibitors**.*Stop spironolactone immediately due to hyperkalaemia and falling eGFR to prevent life-threatening complications*- While hyperkalaemia is a risk, a potassium level of **5.6 mmol/L** is often manageable and does not warrant immediate cessation of a drug with clear **prognostic benefits**.- Abrupt discontinuation of MRAs in HFrEF patients is associated with **increased mortality** and a higher risk of heart failure hospitalisation.*Continue current therapy unchanged as all medications are guideline-indicated and hyperkalaemia is mild*- A potassium level of **5.6 mmol/L** exceeds the normal range and requires active intervention to prevent progression to **severe hyperkalaemia**.- Ignoring persistent hyperkalaemia in the context of **CKD Stage 3b** increases the risk of cardiac arrhythmias and clinical instability.*Reduce ramipril dose to 5mg to address hyperkalaemia while maintaining cardiovascular protection*- Reducing the dose of **ACE inhibitors** like **ramipril** may slightly lower potassium but at the cost of suboptimal **neurohormonal blockade** and reduced survival.- Managing the potassium directly with a binder is preferred over **down-titrating** therapy that is currently at its target evidence-based dose.*Stop dapagliflozin as eGFR is approaching the threshold for discontinuation and it may contribute to hyperkalaemia*- **SGLT2 inhibitors** like **dapagliflozin** can be continued until an **eGFR of 15-20 ml/min/1.73m²** in heart failure according to updated guidelines.- SGLT2 inhibitors actually tend to **reduce the risk** of hyperkalaemia or remain neutral, rather than contributing to it, making discontinuation inappropriate here.
Question 47: A 74-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and orthostatic hypotension attends with his wife who reports he has been experiencing visual hallucinations and increased confusion over the past month. His medications include co-careldopa, ropinirole, selegiline, metformin, tamsulosin, and fludrocortisone. Examination reveals BP 142/86 mmHg sitting, 110/68 mmHg standing. MMSE is 22/30 (previously 26/30 six months ago). When analyzing the interaction between his conditions and medications causing cognitive decline, which medication modification represents the most appropriate initial strategy?
A. Stop fludrocortisone as improved orthostatic hypotension may reduce confusion
B. Reduce co-careldopa dose as excess levodopa commonly causes hallucinations
C. Stop selegiline as MAO-B inhibitors can precipitate confusion and hallucinations
D. Stop ropinirole as dopamine agonists are most likely to cause neuropsychiatric adverse effects including hallucinations and should be withdrawn first (Correct Answer)
E. Add quetiapine to manage hallucinations while continuing current Parkinson's medications
Explanation: ***Stop ropinirole as dopamine agonists are most likely to cause neuropsychiatric adverse effects including hallucinations and should be withdrawn first***- **Dopamine agonists** like ropinirole carry a much higher risk of inducing **visual hallucinations** and cognitive impairment compared to other antiparkinsonian agents.- In the hierarchy of drug withdrawal for Parkinson's psychosis, **dopamine agonists** should always be stopped or tapered first before considering reductions in MAO-B inhibitors or levodopa.*Stop fludrocortisone as improved orthostatic hypotension may reduce confusion*- **Fludrocortisone** is used to manage **orthostatic hypotension**, and stopping it would likely increase the patient's risk of syncope and falls given his significant postural drop (142/86 to 110/68).- While low cerebral perfusion can cause confusion, it does not typically cause the distinct **visual hallucinations** seen in medication-induced Parkinson's psychosis.*Reduce co-careldopa dose as excess levodopa commonly causes hallucinations*- **Levodopa** (co-careldopa) is the most effective drug for motor symptom control and is generally better tolerated cognitively than dopamine agonists.- It should be the **last** medication to be reduced because tapering it prematurely can lead to severe **motor deterioration** and immobility.*Stop selegiline as MAO-B inhibitors can precipitate confusion and hallucinations*- While **MAO-B inhibitors** like selegiline can contribute to neuropsychiatric symptoms, they are generally considered less potent triggers than **dopamine agonists**.- Clinical guidelines recommend withdrawing MAO-B inhibitors only **after** dopamine agonists have been successfully discontinued.*Add quetiapine to manage hallucinations while continuing current Parkinson's medications*- The primary strategy for managing **Parkinson's-related psychosis** is the reduction of offending dopaminergic medications rather than adding and increasing polypharmacy.- **Atypical antipsychotics** like quetiapine or clozapine are reserved for cases where symptoms persist despite the optimization and reduction of Parkinson's therapy.
Question 48: A 68-year-old woman with type 2 diabetes, hypertension, hypothyroidism, osteoporosis, and chronic pain syndrome attends for a medication review. She takes metformin, gliclazide, amlodipine, ramipril, levothyroxine, alendronate with calcium and vitamin D, and co-codamol 30/500 four times daily for 3 years. She reports ongoing lower back pain, constipation requiring regular laxatives, and daytime drowsiness affecting her daily activities. Her HbA1c is 62 mmol/mol. When applying structured medication review principles to optimize her management, which intervention should be prioritized?
A. Reduce gliclazide dose due to risk of hypoglycaemia with daytime drowsiness
B. Switch co-codamol to modified-release morphine for better pain control
C. Initiate a gradual opioid reduction plan with introduction of non-opioid analgesics and non-pharmacological pain management strategies (Correct Answer)
D. Add a stimulant laxative to better manage opioid-induced constipation
E. Switch amlodipine to an alternative antihypertensive as it may be contributing to drowsiness
Explanation: ***Initiate a gradual opioid reduction plan with introduction of non-opioid analgesics and non-pharmacological pain management strategies***- This patient is experiencing clear **opioid-related adverse effects**, including **constipation** and **daytime drowsiness**, secondary to long-term (3 years) high-dose **co-codamol** use.- Evidence-based guidelines for **chronic non-malignant pain** recommend tapering opioids to improve quality of life, as long-term use is associated with limited efficacy and significant harm like **dependence** or **falls risk**.*Reduce gliclazide dose due to risk of hypoglycaemia with daytime drowsiness*- While drowsiness can be a sign of hypoglycemia, the patient's **HbA1c of 62 mmol/mol** suggests her diabetes is currently suboptimal rather than over-controlled.- The sedative effect is more likely attributed to the **codeine** component of her analgesia rather than glucose-lowering therapy.*Switch co-codamol to modified-release morphine for better pain control*- Escalating to a stronger **opioid** like morphine is contraindicated in chronic primary pain and would likely worsen her **side effects** and long-term prognosis.- This approach ignores the principles of **deprescribing** in a patient already suffering from medication-related harm.*Add a stimulant laxative to better manage opioid-induced constipation*- Adding more medication to treat side effects of an existing drug is known as a **prescribing cascade**, which should be avoided in **polypharmacy** management.- Addressing the root cause by reducing the **opioid load** is medical priority over managing the symptom with additional drugs.*Switch amlodipine to an alternative antihypertensive as it may be contributing to drowsiness*- **Amlodipine** is a calcium channel blocker commonly associated with peripheral edema, but it is not a recognized cause of significant **daytime drowsiness**.- Prioritizing an antihypertensive switch would fail to address the high-risk **opioid burden** impacting the patient's daily activities.
Question 49: During a comprehensive medication review for a 70-year-old man with COPD (post-bronchodilator FEV1 45% predicted), type 2 diabetes, ischaemic heart disease, and depression, you identify he is taking 11 regular medications including fluticasone/vilanterol inhaler, tiotropium, carbocisteine, bisoprolol, aspirin, atorvastatin, ramipril, metformin, sertraline, omeprazole, and paracetamol. He has had three chest infections requiring antibiotics in the past 12 months and reports persistent low mood despite sertraline 100mg daily. Applying the principles of medication optimization in multimorbidity, what is the most appropriate action?
A. Add prednisolone 5mg daily as maintenance therapy to reduce COPD exacerbations
B. Switch bisoprolol to a cardioselective alternative as beta-blockers may worsen COPD
C. Add azithromycin prophylaxis three times weekly to reduce exacerbation frequency given recurrent infections
D. Increase sertraline to 150mg daily to optimize antidepressant therapy before considering alternatives
E. Consider referral to pulmonary rehabilitation and address potentially undiagnosed anxiety contributing to breathlessness and depression (Correct Answer)
Explanation: ***Consider referral to pulmonary rehabilitation and address potentially undiagnosed anxiety contributing to breathlessness and depression***
- In patients with **multimorbidity** and high **polypharmacy** (11 medications), non-pharmacological interventions like **pulmonary rehabilitation** are prioritized to improve quality of life and exercise tolerance.
- **Pulmonary rehabilitation** has a strong evidence base for reducing symptoms of both **COPD** and associated **depression** and **anxiety**, addressing multiple comorbidities without increasing the drug burden.
*Add prednisolone 5mg daily as maintenance therapy to reduce COPD exacerbations*
- Maintenance **oral corticosteroids** are not recommended in routine COPD management due to significant side effects like **osteoporosis**, **diabetes worsening**, and increased **infection risk**.
- The patient is already at high risk for infections and has **type 2 diabetes**, making chronic steroid therapy specifically contraindicated in this context.
*Switch bisoprolol to a cardioselective alternative as beta-blockers may worsen COPD*
- **Bisoprolol** is already a **cardioselective beta-blocker**, which is considered safe and indicated for patients with **ischaemic heart disease** even if they have COPD.
- There is no clinical indication to switch, as cardioselective beta-blockers do not cause significant bronchoconstriction in the majority of COPD patients.
*Add azithromycin prophylaxis three times weekly to reduce exacerbation frequency given recurrent infections*
- While **prophylactic antibiotics** can reduce exacerbations, they should only be considered after **pulmonary rehabilitation**, smoking cessation, and inhaler technique have been optimized.
- Adding more medication to a patient already on 11 drugs increases the risk of **adverse drug reactions** and **antimicrobial resistance** unnecessarily at this stage.
*Increase sertraline to 150mg daily to optimize antidepressant therapy before considering alternatives*
- Increasing the dose of **sertraline** contributes to **polypharmacy** and increases the risk of side effects like **hyponatremia** or GI upset in an elderly patient.
- Holistic management requires investigating if **breathlessness-related anxiety** is the driver of low mood before escalating pharmacological treatment for depression.
Question 50: A 75-year-old woman with heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, and chronic kidney disease stage 3a attends for review. She takes bisoprolol, furosemide, spironolactone, apixaban, digoxin, metformin, and atorvastatin. She reports experiencing nausea, visual disturbances with yellow-tinged vision, and palpitations over the past week. Her pulse is irregularly irregular at 48 bpm, BP 118/72 mmHg. ECG shows atrial fibrillation with slow ventricular response and frequent ventricular ectopics. Blood tests show Na+ 136 mmol/L, K+ 5.8 mmol/L, creatinine 142 μmol/L (baseline 125), and eGFR 36 ml/min/1.73m². Applying clinical reasoning to this polypharmacy scenario, what is the most appropriate immediate action?
A. Reduce bisoprolol dose as bradycardia is likely beta-blocker related in the context of declining renal function
B. Stop digoxin immediately and check digoxin level as features suggest toxicity precipitated by hyperkalaemia and worsening renal function (Correct Answer)
C. Stop spironolactone due to hyperkalaemia and worsening renal function, and reassess in 48 hours
D. Reduce furosemide dose as overdiuresis may have precipitated acute kidney injury and electrolyte disturbance
E. Arrange urgent hospital admission for management of hyperkalaemia and bradycardia
Explanation: ***Stop digoxin immediately and check digoxin level as features suggest toxicity precipitated by hyperkalaemia and worsening renal function***
- The patient presents with classic features of **digoxin toxicity**, including gastrointestinal upset (**nausea**), **xanthopsia** (yellow-tinged vision), **bradycardia** (48 bpm), and **ventricular ectopics**.
- Digoxin has a narrow therapeutic window, is primarily **renally excreted**, and its toxicity is exacerbated by **worsening renal function** (elevated creatinine and reduced eGFR) and can cause **hyperkalemia**.
*Reduce bisoprolol dose as bradycardia is likely beta-blocker related in the context of declining renal function*
- While **bisoprolol** contributes to bradycardia, it does not explain the multisystem symptoms like **visual disturbances** or **nausea**, which are hallmarks of digoxin toxicity.
- Bisoprolol is metabolized by both the liver and kidneys, so while renal impairment is a factor, the overall clinical picture points to a more specific drug toxicity.
*Stop spironolactone due to hyperkalaemia and worsening renal function, and reassess in 48 hours*
- **Spironolactone** is an important contributor to **hyperkalemia** and should be reviewed, especially with worsening renal function.
- However, stopping spironolactone alone does not address the acute, potentially life-threatening cardiac and neurological symptoms of **digoxin toxicity**, which is the more immediate concern.
*Reduce furosemide dose as overdiuresis may have precipitated acute kidney injury and electrolyte disturbance*
- The patient's blood pressure (118/72 mmHg) does not strongly suggest severe **volume depletion** from overdiuresis that would precipitate acute kidney injury in this context.
- Reducing **furosemide** would not address the acute presentation of **digoxin toxicity**, which is the primary cause of her current symptoms.
*Arrange urgent hospital admission for management of hyperkalaemia and bradycardia*
- While hospital admission may be necessary for comprehensive management, the **most appropriate immediate action** in this scenario is to first discontinue the suspected offending agent, **digoxin**, to prevent further accumulation and worsening toxicity.
- A potassium of **5.8 mmol/L** and heart rate of **48 bpm** in a patient with clear signs of drug toxicity mandate immediate drug cessation and evaluation, which can often precede or be initiated prior to formal admission.
